a1-Solcia E, Kloppel G, Sobin LH.. Histological typing on endocrine tumors.

In: WHO
International Classification of Tumors, 2nd, Springer, Berlin, Germany 2000.

a2-Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine
tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.

b3-Kuo JH, Lee JA, Chabot JA. Nonfunctional pancreatic neuroendocrine tumors. SurgClin
North Am. 2014;94:689–708. doi: 10.1016/j.suc.2014.02.010. [PubMed]

c4-Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of
pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1766.

D5-Yao JC, Hassan M, Phan A, et al. One

hundred years after “carcinoid”: epidemiology
of and prognostic factors for neuroendocrine
tumors in 35,825 cases in the
United States. J Clin Oncol 2008;26:3063-
72

E6. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical

management of pancreatic neuroendocrine tumors. Am J Gastroenterol.
2008;103:475–83. doi: 10.1111/j.1572-0241.2007.01643.x. [PubMed] [Cross Ref]

E7. Ehehalt F, Saeger HD, Schmidt CM, Grützmann R. Neuroendocrine tumors of the
pancreas. Oncologist. 2009;14:456–67. doi: 10.1634/theoncologist.2008-0259.
[PubMed] [Cross Ref]

F8. Howell DL, O’Dorisio MS. Management of neuroendocrine tumors in children,

adolescents, and young adults. J Pediatr Hematol Oncol. 2012;34(Suppl 2):S64–68.
doi: 10.1097/MPH.0b013e31824e3885. [PubMed] [Cross Ref]

F9. Lachter J, Arkovitz MS, Postovski S, Waldner JM, Shaoul R, Ishay OB, et al.
EUS-FNA for a pancreatic neuroendocrine tumor in a four-year-old daughter of a
woman exposed to radiation at Chernobyl. Case Rep Gastrointest Med.
2012;2012:462139. [PMC free article] [PubMed]

H10-Kuo JH, Lee JA, Chabot JA. Nonfunctional pancreatic neuroendocrine

tumors. SurgClin North Am. 2014;94:689–708. doi:
10.1016/j.suc.2014.02.010. [PubMed]

I11-. Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O’Connor JM, et al. ENETS
Consensus Guidelines for the management of patients with digestive neuroendocrine
neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.
Neuroendocrinology. 2012;95:120–34. doi: 10.1159/000335587. [PubMed] [Cross Ref]

G12-Kuo JH, Lee JA, Chabot JA. Nonfunctional pancreatic neuroendocrine

tumors. SurgClin North Am. 2014;94:689–708. doi:
10.1016/j.suc.2014.02.010. [PubMed]
K13-Yao JC, Hassan M, Phan A, et al. One
hundred years after “carcinoid”: epidemiology
of and prognostic factors for neuroendocrine
tumors in 35,825 cases in the
United States. J Clin Oncol 2008;26:3063-
72

Pubmed 1 metasta

Pubmed 2 a rare

Nejm Everolimus for Advanced Pancreatic

Neuroendocrine Tumors

Up to date Classification, epidemiology, clinical presentation,

localization, and staging of pancreatic neuroendocrine tumors

Pnets tumors are rare tumors and no clear therapeutic guidelines

exist, in our case the patient was put on chemotherapy and of( cisplatin and
.etoposid) and the patient showed good response on Echography and Ct

]Pnets often give metastasis to liver and bones. [7

in our case distant metastasis were fiund initially in the mediastinum